Advanced lung cancer

Early data from two clinical trials have shown reduced survival with Keytruda ( Pembrolizumab ) and Tecentriq ( Atezolizumab )...


The European Commission has granted marketing authorisation for Tagrisso ( Osimertinib ), a third-generation, irreversible EGFR-TKI, as monotherapy for the...


Alectinib ( Alecensa ) has proven systemic and CNS efficacy in patients with ALK+ aNSCLC ( advanced non-small cell lung...


Despite advancement of 2nd generation ALK tyrosine kinase inhibitors ( TKIs ), patients with ALK+ non-small cell lung cancer ...


CheckMate 227, a phase 3 study of first-line Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ), Nivolumab, or Nivolumab...


CheckMate 227 is a large phase 3 study of first-line Nivolumab plus Ipilimumab, Nivolumab, or Nivolumab plus chemotherapy vs chemotherapy...


The phase 2 ATLANTIC study has investigated the anti-PD-L1 antibody Durvalumab ( Imfinzi ) in heavily pretreated patients with advanced...


The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has...


The FDA ( U.S. Food and Drug Administration ) has approved Imfinzi ( Durvalumab ) for the treatment of patients...


The FDA ( U.S. Food and Drug Administration ) has approved Imfinzi ( Durvalumab ) for the treatment of patients...


In a letter published in the cancer journal Annals of Oncology, researchers led by Jean-Philippe Spano, at Pitie-Salpetriere Hospital AP-HP...


Researchers at the University of Texas MD Anderson Cancer Center in Houston, have found a link between microbes in the...


The FDA ( Food and Drug Administration ) has granted full approval for Tagrisso ( Osimertinib ) 80mg once-daily tablets,...


Treatment with the immune checkpoint inhibitor Nivolumab ( Opdivo ) has yielded durable responses in some patients with advanced non-small...


Agents that induce an immune response against tumors by altering T-cell regulation have increased survival times of patients with advanced-stage...


In non-small cell lung cancer ( NSCLC ) that has already formed metastases, the suitable treatment depends, among other factors,...



The U.S. Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, for the...


Updated data from the advanced non-small cell lung cancer ( NSCLC ) patient cohort of the ongoing phase 1/2 ECHO-202...


Updated data from the ongoing phase 1/2 ECHO-204 trial evaluating the safety and efficacy of Epacadostat, an oral selective IDO1...